FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.900,98 -1.248,04 (-2,07%)
Organovo Holdings, Inc. (0R02.L)
| Chiusura precedente | 0,9900 |
| Aperto | 0,9801 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,9801 - 0,9801 |
| Intervallo di 52 settimane | 0,9800 - 2,2200 |
| Volume | |
| Media Volume | 565 |
| Capitalizzazione | 548.582 |
| Beta (5 anni mensile) | 0,90 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3150 |
| Prossima data utili | 11 lug 2024 - 15 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireOrganovo to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co
- GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral
